Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
received:
17
04
2023
accepted:
03
06
2024
medline:
15
6
2024
pubmed:
15
6
2024
entrez:
14
6
2024
Statut:
epublish
Résumé
Several population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none have examined multimorbidity. Others have shown that suboptimal post-vaccination responses offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of protection from COVID-19 hospitalisation/death remains unconfirmed. We use national Scottish datasets to investigate the association between multimorbidity and testing antibody-negative, examining the correlation between antibody levels and subsequent COVID-19 hospitalisation/death among double-vaccinated individuals. We found that individuals with multimorbidity ( ≥ five conditions) were more likely to test antibody-negative post-vaccination and 13.37 [6.05-29.53] times more likely to be hospitalised/die from COVID-19 than individuals without conditions. We also show a dose-dependent association between post-vaccination antibody levels and COVID-19 hospitalisation or death, with those with undetectable antibody levels at a significantly higher risk (HR 9.21 [95% CI 4.63-18.29]) of these serious outcomes compared to those with high antibody levels.
Identifiants
pubmed: 38877008
doi: 10.1038/s41541-024-00898-w
pii: 10.1038/s41541-024-00898-w
doi:
Types de publication
Journal Article
Langues
eng
Pagination
107Subventions
Organisme : RCUK | Medical Research Council (MRC)
ID : MC_PC_19075
Informations de copyright
© 2024. The Author(s).
Références
Public Health Scotland. COVID-19 vaccine information and resources. https://publichealthscotland.scot/our-areas-of-work/conditions-and-diseases/covid-19/covid-19-vaccinations/covid-19-vaccine-information-and-resources/eligible-groups/ (2023).
Kerr, S., Vasileiou, E., Robertson, C. & Sheikh, A. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland. J. Glob. Health 12, 05025 (2022).
doi: 10.7189/jogh.12.05025
pubmed: 35802764
pmcid: 9269984
Florentino, P. T. V. et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. Lancet Infect. Dis. 22, 1577–1586 (2022).
doi: 10.1016/S1473-3099(22)00451-0
pubmed: 35952702
pmcid: 9359673
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
doi: 10.1038/s41591-021-01377-8
pubmed: 34002089
Dimeglio, C. et al. Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection. Vaccines (Basel) 10, 1548 (2022).
doi: 10.3390/vaccines10091548
pubmed: 36146626
Jolliffe, D. A. et al. Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK). Vaccines (Basel) 10, 1601 (2022).
doi: 10.3390/vaccines10101601
pubmed: 36298466
Ward, H. et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun. 13, 907 (2022).
doi: 10.1038/s41467-022-28527-x
pubmed: 35173150
pmcid: 8850615
Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2022).
doi: 10.1126/science.abm3425
pubmed: 34812653
Perry, J. et al. Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS One 17, e0266852 (2022).
doi: 10.1371/journal.pone.0266852
pubmed: 35395052
pmcid: 8993021
Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032–2040 (2021).
doi: 10.1038/s41591-021-01540-1
pubmed: 34588689
pmcid: 8604724
Goldblatt, D. et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine 40, 306–315 (2022).
doi: 10.1016/j.vaccine.2021.12.006
pubmed: 34933765
Cheetham, N. J. et al. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies. Elife 12, e80428 (2023).
doi: 10.7554/eLife.80428
pubmed: 36692910
pmcid: 9940912
Agrawal, U. et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir. Med. 9, 1439–1449 (2021).
doi: 10.1016/S2213-2600(21)00380-5
pubmed: 34599903
pmcid: 8480963
Agrawal, U. et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet 400, 1305–1320 (2022).
doi: 10.1016/S0140-6736(22)01656-7
pubmed: 36244382
pmcid: 9560746
Martin-Vicente, M. et al. Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. J. Intern Med. 291, 232–240 (2022).
doi: 10.1111/joim.13386
pubmed: 34611927
Liu, X. et al. Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China. Aging (Albany NY) 12, 12432–12440 (2020).
doi: 10.18632/aging.103417
pubmed: 32628642
Asif, S. et al. Weak anti-SARS-CoV-2 antibody response is associated with mortality in a Swedish cohort of COVID-19 patients in critical care. Crit. Care 24, 639 (2020).
doi: 10.1186/s13054-020-03362-y
pubmed: 33158455
pmcid: 7645408
Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644 (2021).
doi: 10.1038/s41586-021-03207-w
pubmed: 33461210
pmcid: 8221082
Alshammary, A. F. et al. T-Cell Subsets and Interleukin-10 Levels Are Predictors of Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. Front. Med. (Lausanne) 9, 852749 (2022).
doi: 10.3389/fmed.2022.852749
pubmed: 35572964
Monin, L. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 22, 765–778 (2021).
doi: 10.1016/S1470-2045(21)00213-8
pubmed: 33930323
pmcid: 8078907
Parry, H. et al. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 11, 136 (2021).
doi: 10.1038/s41408-021-00528-x
pubmed: 34330895
pmcid: 8323747
Kara, Z. et al. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity. Obes. Surg. 32, 2987–2993 (2022).
doi: 10.1007/s11695-022-06181-y
pubmed: 35802279
pmcid: 9263798
Nasr, M. C., Geerling, E. & Pinto, A. K. Impact of Obesity on Vaccination to SARS-CoV-2. Front Endocrinol. (Lausanne) 13, 898810 (2022).
doi: 10.3389/fendo.2022.898810
pubmed: 35795152
Liao, S., Gerber, A. N., Zelarney, P., Make, B. & Wechsler, M. E. Impaired SARS-CoV-2 mRNA Vaccine Antibody Response in Chronic Medical Conditions: A Real-World Analysis. Chest 161, 1490–1493 (2022).
doi: 10.1016/j.chest.2021.12.654
pubmed: 35016912
Shrotri, M. et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 398, 385–387 (2021).
doi: 10.1016/S0140-6736(21)01642-1
pubmed: 34274038
pmcid: 8285117
Notarte, K. I. et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit. Rev. Clin. Lab Sci. 59, 373–390 (2022).
doi: 10.1080/10408363.2022.2038539
pubmed: 35220860
Hou, Y., Lu, K. & Kuo, K. The efficacy of COVID-19 vaccines in chronic kidney disease and kidney transplantation patients: a narrative review. Vaccines (Basel) 9, 885 (2021).
Schinas, G. et al. COVID-19 Vaccination in Patients with Chronic Liver Disease. Viruses 14, 2778 (2022).
doi: 10.3390/v14122778
pubmed: 36560782
pmcid: 9785164
Ward, V. et al. SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study. BMJ Open 12, e066766 (2022).
doi: 10.1136/bmjopen-2022-066766
pubmed: 36456004
Greenberger, L. M. et al. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell 39, 1031–1033 (2021).
doi: 10.1016/j.ccell.2021.07.012
pubmed: 34331856
pmcid: 8295014
Lee, A. R. Y. B. et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 376, e068632 (2022).
doi: 10.1136/bmj-2021-068632
pubmed: 35236664
Lee, L. Y. W. et al. Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation. JAMA Oncol. 9, 188–196 (2023).
doi: 10.1001/jamaoncol.2022.5974
pubmed: 36547970
Gombolay, G. Y., Dutt, M. & Tyor, W. Immune responses to SARS‐CoV‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis. Ann. Clin. Transl. Neurol. 9, 1321–1331 (2022).
doi: 10.1002/acn3.51628
pubmed: 35852423
pmcid: 9349877
Wei, J. et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. 28, 1072–1082 (2022).
doi: 10.1038/s41591-022-01721-6
pubmed: 35165453
pmcid: 9117148
Karachaliou, M. et al. SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia. BMC Med. 20, 347 (2022).
doi: 10.1186/s12916-022-02547-2
pubmed: 36109713
pmcid: 9479347
Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 386, 1532–1546 (2022).
doi: 10.1056/NEJMoa2119451
pubmed: 35249272
Nielsen, K. F. et al. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. PLoS Med. 19, e1004037 (2022).
doi: 10.1371/journal.pmed.1004037
pubmed: 36413551
pmcid: 9681105
Schmidt, T. et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat. Med. 27, 1530–1535 (2021).
doi: 10.1038/s41591-021-01464-w
pubmed: 34312554
pmcid: 8440177
Mulholland, R. H. et al. Cohort Profile: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) Database. Int. J. Epidemiol. 50, 1064–1074 (2021).
doi: 10.1093/ije/dyab028
pubmed: 34089614
Palmateer, N. E. et al. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. Public Health 198, 102–105 (2021).
doi: 10.1016/j.puhe.2021.07.006
pubmed: 34411992
Public Health Scotland. Enhanced Surveillance of COVID-19 in Scotland. https://publichealthscotland.scot/publications/enhanced-surveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-population-based-seroprevalence-surveillance-3-august-2022/ (2022).
DiaSorin. LIAISON SARS-CoV-2 TrimericS IgG assay: A quantitative assay for immune status monitoring with an accurate correlation of neutralizing IgG antibodies. https://int.diasorin.com/en/immunodiagnostics/infectious-diseases/sars-cov-2-diagnostic-solutions (2023).
Clift, A. K. et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 371, m3731 (2020).
doi: 10.1136/bmj.m3731
pubmed: 33082154